• Home
  • Contactez nous

  • Financer
  • Divertissement
  • Science
  • Sport
  • Monde
  • Médecine
  • France
  • Local

Analyst Stock Ratings: Sucampo Pharmaceuticals, Inc. (SCMP), Caesars Entertainment Corporation (CZR)

  • by Xavier Trudeau
  • in Financer
  • — Jan 13, 2018
Share:

The stock exchanged hands with 9,322,450 numbers of shares compared to its average daily volume of 4.83M shares. SCMP was included in 3 notes of analysts from September 7, 2016. Analysts reported that the Price Target for Sucampo Pharmaceuticals, Inc. might touch $43 high while the Average Price Target and Low price Target is $21.29 and $11 respectively. Mizuho upgraded the stock to "Buy" rating in Thursday, December 22 report.

The consensus analysts recommendation at this point stands at 2.70 on Sucampo Pharmaceuticals, Inc. Maxim Group lowered shares of Sucampo Pharmaceuticals to a "hold" rating in a research note on Monday, January 1st. Finally, Globeflex Capital L P increased its stake in shares of Sucampo Pharmaceuticals by 0.3% in the second quarter. SCMP's profit will be $15.96 million for 13.51 P/E if the $0.34 EPS becomes a reality.

Among 10 analysts covering Coherus Biosciences (NASDAQ:CHRS), 9 have Buy rating, 0 Sell and 1 Hold. The stock presently has a consensus rating of "Buy" and an average price target of $21.58. (NASDAQ:SCMP). Ativo Capital Management Lc has 0.4% invested in Sucampo Pharmaceuticals, Inc. The company has market cap of $849.64 million. The company has market cap of $223.66 million. The stock, as of last close, traded 97.85% away to its 52 week low and was at a distance of 1.10% from its 52 week high.

Equities researchers at Leerink Swann raised their FY2019 earnings per share estimates for shares of Sucampo Pharmaceuticals in a research note issued on Monday, Zacks Investment Research reports. After $-0.68 actual earnings per share reported by Syndax Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 36.76% negative EPS growth. The company's net profit margin has achieved the current level of -60.2 percent and possesses 72.8 percent gross margin. The business had revenue of $61.27 million during the quarter, compared to analysts' expectations of $58.05 million. The low EPS estimate is $0.25, while the high EPS estimate is $0.36. The company reported the earnings of $0.27/Share in the last quarter where the estimated EPS by analysts was $0.25/share.

  • Trump Accuses FBI Agent in Clinton Probe of 'Treason'

In other Sucampo Pharmaceuticals news, insider Peter A. Kiener sold 50,000 shares of the stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $16.86, for a total transaction of $337,200.00. SCMP's SI was 4.69 million shares in January as released by FINRA. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Arizona State Retirement System grew its position in Sucampo Pharmaceuticals by 1.6% during the second quarter. Rhumbline Advisers raised its holdings in shares of Sucampo Pharmaceuticals by 0.9% in the second quarter.

The stock decreased 1.63% or $0.3 during the last trading session, reaching $18.1. UBS downgraded Sucampo Pharmaceuticals, Inc. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company's stock valued at $126,000 after purchasing an additional 631 shares during the last quarter. Vanguard Group Inc. now owns 1,646,348 shares of the biopharmaceutical company's stock valued at $17,287,000 after buying an additional 189,561 shares in the last quarter. The Manufacturers Life Insurance Company now owns 19,983 shares of the biopharmaceutical company's stock valued at $209,000 after buying an additional 790 shares during the period. Rhumbline Advisers now owns 48,810 shares of the biopharmaceutical company's stock valued at $513,000 after buying an additional 423 shares during the period. Company insiders own 3.31% of the company's stock. If you are accessing this report on another site, it was stolen and reposted in violation of global copyright & trademark law. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & worldwide copyright legislation. The original version of this report can be read at [[permalink]].

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company's product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders.

Share:

IN CASE YOU MISSED IT

  • Oprah Delivers Inspiring Speech for Cecil B. DeMille Award at Golden Globes
  • Chopper with 7 on board goes missing off Mumbai coast
  • Louisville rallies to beat No. 23 Florida State
  • YOU MAY ALSO LIKE...

    • After A Tough Year For YouTube, Alphabet Revenue Growth Still Looks Unstoppable 4/24/2018
    • Open Britain set to hold Aylesbury campaign on Brexit final deal 4/24/2018
    • 9 dead, 16 injured in Toronto van crash 4/24/2018
    • Active Stock on Watch: Kapstone Paper and Packaging Corp (KS) Runs 4/24/2018
    • Deutsche Bank AG Grows Position in Sabra Health Care REIT (NASDAQ:SBRA) 4/24/2018
    • Pfizer INC (PFE) Shareholder Jpmorgan Chase & Company Increased Stake by $52.85 Million 4/24/2018
    • VTNA President Göran Nyberg Moves to VW Bus and Truck Division 4/24/2018
    • Kimberly-Clark results beat as tissue sales climb 4/24/2018
    • Raghuram Rajan may be in running for BoE guv 4/24/2018
    • Ferroglobe PLC (GSM) Analysts See $0.19 EPS on May, 21 4/24/2018

RELATED NEWS

La palla passa al Barcellona
Il dubbio maggiore riguarda le condizioni fisiche del brasiliano, fermo da 8 mesi a causa di una lesione al menisco. In queste ore Alex Boesch e Mazinho , rispettivamente agente e padre del giocatore, stanno valutando la proposta.
1/13/2018

Le gros regret de Claudio Ranieri — Mercato FC Nantes
"Dans le jeu, on avait réussi à répondre présents", a annoncé le joueur du FC Nantes devant la presse. Malgré la complexité du dossier, l'homme d'affaires polonais s'est activé afin d'arriver à ses fins.
1/13/2018

U.S. oil output to surpass record earlier than expected
Most of the growth in USA output will come from the Permian basin, a huge shale region spanning western Texas and New Mexico. Despite the rising production, oil prices traded higher on Tuesday, with US crude touching its highest since December 2014.
1/13/2018

Wynn Resorts (WYNN) Given Coverage Optimism Score of 0.12
Kayne Anderson Rudnick Inv Mgmt Llc has 0.32% invested in Wynn Resorts, Limited (NASDAQ:WYNN) for 238,466 shares. Mackenzie Financial Corp increased Allergan Plc stake by 268,705 shares to 608,008 valued at $124.61M in 2017Q3.
1/13/2018

India takes on major role in fighting climate change: Guterres
Guterres told United Nations member countries on Thursday that the migrant issue is one of the top priorities for 2018. The G77 is a coalition of developing countries that works collectively on development and worldwide economic issues.
1/13/2018

Patrick Corbin, Diamondbacks reach $7.5M, one-year deal, avoid salary arbitration
BC-BBN-Arbitration-Diamondbacks, 2nd Ld-Writethru, 309 Dbacks settle with Pollock, Lamb, Ray, avoid arbitrationEds: Adds Pollock. Pollock and David Peralta ; shortstops Chris Owings and Nick Ahmed ; catcher Chris Herrmann ; and third baseman Jake Lamb .
1/13/2018

Bruins snowed-out game move to April 8, thanks to Celtics
The Bruins will make up their snowed-out game against the Florida Panthers on April 8 at the TD Garden. It was eventually pushed back to April 25.
1/13/2018

Mads Ostberg disputera le Rallye de Suède avec Citroën
Cette équipe est une équipe formidable, j'ai travaillé avec eux par le passé et je sais ce qu'il vaut" à déclaré le norvégien. Le constructeur s'est adjoint les services de Mads Ostberg pour le rallye de Suède, en WRC .
1/13/2018

Yoel Romero to replace middleweight champ Robert Whittaker at UFC 221
A former Cuban Olympic silver-medalist wrestler, Romero was scheduled to face Branch at a UFC Fight Night event on February 24. Whittaker (19-4) won an interim middleweight title last July at UFC 213 with a unanimous decision win over Romero.
1/13/2018

Renacci joins Senate race against Brown
Sherrod Brown, but he said Friday he is the "total opposite" from Brown, a career politician. But Cohen said he believes it would not help Renacci in a general election against Brown.
1/13/2018

After Rajasthan, Gujarat and Madhya Pradesh ban Padmaavat
Madhya Pradesh chief minister Shivraj Singh Chouhan stand against the film hasn't changed even after Padmavati becomes Padmaavat . After much delay, the CBFC finally chose to release the film on January 25 this year albeit with a few changes.
1/13/2018

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director Stephen L. Sabba Sells 925 Shares
With 287,200 avg volume, 13 days are for Ligand Pharmaceuticals (NASDAQ:LGND)'s short sellers to cover LGND's short positions. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is worth US$3.06 Billion and has recently risen 2.21% to US$144.25.
1/13/2018

Steve Wilks won't interview for Colts head coaching job
The Panthers finished in the top 10 in the National Football League in total defense, rushing defense and scoring defense in 2017. We've already written a comprehensive profile of Wilks ' résumé and his possible fit as the Colts' next head coach.
1/13/2018

Delta Air Lines, Inc. (DAL) President Sells 31600 Shares of Stock
Louis Bacon decreased its stake in Delta Air Lines Inc (DAL) by 44.44% based on its latest 2017Q3 regulatory filing with the SEC. Tracking most recent quarter period, Price to book (P/B) ration is at 2.77 and Price to cash per share ration is at 15.91.
1/13/2018

Jags RB Leonard Fournette says his two best plays came against Steelers
In 1993, his fifth season, Aikman completed 271 passes for 3,100 yards with 15 touchdowns and six interceptions. Asked if he is disappointed by Brown's injury, coach Doug Marrone said: "I don't think we're there yet".
1/13/2018

    • Top picks

      • After A Tough Year For YouTube, Alphabet Revenue Growth Still Looks Unstoppable4/24/2018
      • Open Britain set to hold Aylesbury campaign on Brexit final deal4/24/2018
      • 9 dead, 16 injured in Toronto van crash4/24/2018
      • Active Stock on Watch: Kapstone Paper and Packaging Corp (KS) Runs4/24/2018
    • Weekly News

      • Deutsche Bank AG Grows Position in Sabra Health Care REIT (NASDAQ:SBRA)4/24/2018
      • Pfizer INC (PFE) Shareholder Jpmorgan Chase & Company Increased Stake by $52.85 Million4/24/2018
      • VTNA President Göran Nyberg Moves to VW Bus and Truck Division4/24/2018
      • Kimberly-Clark results beat as tissue sales climb4/24/2018
    • Latest News

      • Amazon, Netflix And Studios Sue Streaming Service Set TV Over Piracy4/24/2018
      • Time to Buy McDermott International, Inc. (MDR) After Today's Huge Increase?4/24/2018
      • Morning Fast-Moving Stocks: MGM Resorts International (NYSE:MGM), Cerner Corporation (NASDAQ:CERN)4/24/2018
      • Marathon Oil (MRO) Shares Bought by Xact Kapitalforvaltning AB4/24/2018
    • Home
    • Contactez nous

    Mardi 24 Avril 2018

    © 2018 . ALL RIGHTS RESERVED.